Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.

PURPOSE To indentify genetic variation that can modulate and predict the risk of developing thalidomide-related peripheral neuropathy (TrPN). PATIENTS AND METHODS We analyzed DNA from 1,495 patients with multiple myeloma. Using a custom-built single nucleotide polymorphism (SNP) array, we tested the association of TrPN with 3,404 SNPs. The SNPs were selected in predicted functional regions within 964 genes spanning 67 molecular pathways thought to be involved in the pathogenesis, treatment response, and adverse effects associated with myeloma and its therapy. Patient cases and controls were derived from two large clinical trials that compared thalidomide with conventional-based treatment in myeloma patients (Medical Research Council Myeloma-IX and HOVON-50/GMMG-HD3). RESULTS We report TrPN associations with SNPs-ABCA1 (rs363717), ICAM1 (rs1799969), PPARD (rs2076169), SERPINB2 (rs6103), and SLC12A6 (rs7164902)-where we show cross validation of the associations in both trials. To investigate whether TrPN SNP associations were related to exposure to thalidomide only or general drug-related peripheral neuropathy, we performed a second analysis on patients treated with vincristine. We report SNPs associated with vincristine neuropathy, with a seemingly distinct underlying genetic mechanism. CONCLUSION Our results are consistent with the hypothesis that an individual's risk of developing a peripheral neuropathy after thalidomide treatment can be mediated by polymorphisms in genes governing repair mechanisms and inflammation in the peripheral nervous system. These findings will contribute to the development of future neuroprotective strategies with thalidomide therapy and the better use of this important compound.

[1]  A. Daly,et al.  Genome-wide association studies in pharmacogenomics , 2010, Nature Reviews Genetics.

[2]  O. Stephens,et al.  Genetic polymorphisms of EPHX1, Gsk3β, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma , 2009, Leukemia.

[3]  Xiang Chen,et al.  Willows: a memory efficient tree and forest construction package , 2009, BMC Bioinformatics.

[4]  S. Iida,et al.  A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma. , 2009, Clinical lymphoma & myeloma.

[5]  Faith,et al.  Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. , 2008, Blood.

[6]  M. Steinbach,et al.  Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival , 2008, BMC medicine.

[7]  A. Argyriou,et al.  A review on oxaliplatin-induced peripheral nerve damage. , 2008, Cancer treatment reviews.

[8]  S. Steinberg,et al.  ABCB1 genetic variation influences the toxicity and clinical outcome of patients treated with docetaxel , 2008 .

[9]  Hua Jiang,et al.  Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide-based regimens in multiple myeloma , 2007, Haematologica.

[10]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[11]  Min Goo Lee,et al.  MRP2 haplotypes confer differential susceptibility to toxic liver injury , 2007, Pharmacogenetics and genomics.

[12]  Lippincott-Schwartz,et al.  Supporting Online Material Materials and Methods Som Text Figs. S1 to S8 Table S1 Movies S1 to S3 a " Silent " Polymorphism in the Mdr1 Gene Changes Substrate Specificity Corrected 30 November 2007; See Last Page , 2022 .

[13]  H. Kroemer,et al.  Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex , 2007, The Pharmacogenomics Journal.

[14]  S. Steinberg,et al.  Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. , 2006, European journal of cancer.

[15]  M. Huang,et al.  A Mechanistic Study on Reduced Toxicity of Irinotecan by Coadministered Thalidomide, a Tumor Necrosis Factor-α Inhibitor , 2006, Journal of Pharmacology and Experimental Therapeutics.

[16]  H. Adelsberger,et al.  Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study , 2006, Investigational New Drugs.

[17]  Cheng Li,et al.  Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. , 2006, Blood.

[18]  L. Mileshkin,et al.  The troublesome toxicity of peripheral neuropathy with thalidomide , 2006, Leukemia & lymphoma.

[19]  Yi Dai,et al.  Induction of plasminogen activator inhibitor-1 and -2 in dorsal root ganglion neurons after peripheral nerve injury , 2005, Neuroscience.

[20]  Joshua T. Burdick,et al.  Mapping determinants of human gene expression by regional and genome-wide association , 2005, Nature.

[21]  B. Palmer,et al.  Metabolism of Thalidomide in Liver Microsomes of Mice, Rabbits, and Humans , 2004, Journal of Pharmacology and Experimental Therapeutics.

[22]  G. Cavaletti,et al.  Thalidomide sensory neurotoxicity , 2004, Neurology.

[23]  M. Ermani,et al.  Thalidomide neurotoxicity , 2004, Neurology.

[24]  Y. Sugiyama,et al.  Characterization of the Cellular Localization, Expression Level, and Function of SNP Variants of MRP2/ABCC2 , 2004, Pharmaceutical Research.

[25]  S. Batalov,et al.  A gene atlas of the mouse and human protein-encoding transcriptomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Palumbo,et al.  Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features , 2004, Acta neurologica Scandinavica.

[27]  J. Marsden,et al.  Thalidomide-induced neuropathy and genetic differences in drug metabolism , 1995, European Journal of Clinical Pharmacology.

[28]  C. Hess,et al.  Thalidomide-induced peripheral neuropathy , 1986, Journal of Neurology.

[29]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[30]  S. Rossi,et al.  Thalidomide-induced neuropathy: A ganglionopathy? , 2003, Neurology.

[31]  D. Cornblath,et al.  Thalidomide-induced neuropathy , 2002, Neurology.

[32]  J. Bouchard,et al.  Erratum: The K-Cl cotransporter KCC3 is mutant in a severe peripheral neuropathy associated with agenesis of the corpus callosum (Nature Genetics (2002) 32(384-392)) , 2002 .

[33]  Y. Ando,et al.  Pharmacogenetic Associations of CYP2C19 Genotype with In Vivo Metabolisms and Pharmacological Effects of Thalidomide , 2002, Cancer biology & therapy.

[34]  J. Bouchard,et al.  The K–Cl cotransporter KCC3 is mutant in a severe peripheral neuropathy associated with agenesis of the corpus callosum , 2002, Nature Genetics.

[35]  W. Figg,et al.  Thalidomide metabolism by the CYP2C subfamily. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  Y. Sugiyama,et al.  Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5'-untranslated region and exon 28. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[37]  J. Hirschhorn,et al.  A comprehensive review of genetic association studies , 2002, Genetics in Medicine.

[38]  S. Strittmatter,et al.  Small Proline-Rich Repeat Protein 1A Is Expressed by Axotomized Neurons and Promotes Axonal Outgrowth , 2002, The Journal of Neuroscience.

[39]  D. Ganesh Rao,et al.  Thalidomide neuropathy: Role of F‐wave monitoring , 2000, Muscle & nerve.

[40]  M. Dimopoulos,et al.  Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent , 2000, Bone Marrow Transplantation.

[41]  J. Shupack,et al.  Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. , 1996, Journal of the American Academy of Dermatology.